QT prolongation

(Redirected from QTc prolongation)

Background

SinusRhythmLabels.svg
Grid.png
  • Prolonged ventricular repolarization → increased risk of ventricular arrhythmias
    • Males >440-450 ms
    • Females >500 ms
    • Rule of thumb: Normal QT interval is less than half of preceding RR interval
  • QT interval is from the beginning of the Q wave to the end of the T wave
    • Rate dependent and should become proportionately shorter with increasing heart rate

List of Drugs Causing QT Prolongation

Clinical Features

  • Most are asymptomatic
  • History may include:
  • Medication history may include QT prolonging medications

Differential Diagnosis

Syncope Causes

Evaluation

Workup

  • ECG
  • CBC
  • Chem 10

Diagnosis

Acquired QT prolongation
  • ECG
    • On visual inspection, QT takes up more than half the R-R distance
    • Measure QT interval in lead II or V5-6
    • QTc = QT /√R-R

Determining Cause

Management

Pause Dependent (precipitated by bradycardia)

Adrenergic Dependent (precipited by tachycardia)

Disposition

  • Consider admission, especially for QT >500 or if symptomatic
  • May require consultation for discontinuation of QT prolonging medications
  • Avoid prescribing medications that may contribute to prolonged QT

See Also

Calculators

Corrected QT Interval (QTc)

Corrected QT Interval (QTc)
Parameter Value
QT Interval (ms)
Heart Rate (bpm)
RR Interval (ms) — auto-calculated from HR ms
Results
QTc (Bazett's) — QT / √(RR in sec) ms
QTc (Fridericia) — QT / ∛(RR in sec) ms
Interpretation (Bazett's QTc)
<440 ms Normal QTc for males.
<460 ms Normal QTc for females.
440–500 ms Borderline/Prolonged — Monitor closely. Review medications for QT-prolonging drugs.
>500 ms Significantly prolonged — High risk for Torsades de Pointes. Discontinue offending agents. Check Mg²⁺/K⁺/Ca²⁺.
References
  • Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.
  • Fridericia LS. Duration of systole in electrocardiogram. Acta Med Scand. 1920;53:469-486.
  • Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625-1633. PMID 10560690.

External Links

References

  1. Simon HL, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol. 2016 Mar; 81(3): 420–427. doi: 10.1111/bcp.12726